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Oesopharyngeal brush (OPB) sampling with cytological analysis can yield exfoliated cells from asymptomatic tumours of the upper
aero-digestive tract and the oesophagus. In this study, we compared cytological evaluation and molecular analysis for the detection of
exfoliated cancer cells sampled with an OPB. A total of 56 patients with a known unique head and neck squamous cell carcinoma
(HNSCC) and five healthy controls were enrolled prospectively. Exfoliated cells from these 61 patients were collected with an OPB
before initial endoscopy. p53 mutations and UT 5085 microsatellite instability (MI) were analysed in the HNSCC tumour, lymphocytes
and the corresponding OPB DNA samples. p53 mutations and UT5085 MI were detected in 31 out of 56 and 14 out of 56 HNSCC,
respectively, but not in any of the five controls. Direct sequencing of p53 was able to detect mutations in OPB DNA in only two out of
29 patients harbouring a p53-mutated primary tumour. Microsatellite instability was detected in OPB DNA of 11 out of 13 informative
(bandshift detected in tumour) patients, whereas cytological analysis detected abnormal cells in only six of the same 13 patients
(P¼0.03). In informative patients, all positive OPB samples at cytological analysis were also positive at molecular analysis of UT5085,
and both analyses confirmed the two negative samples. Molecular analysis of OPB from eight uninformative patients and from five
healthy controls were all negative. OPB sampling with MI-based molecular analysis could be efficient for early detection of recurrent
HNSCC. This result prompts us to use other microsatellite markers in order to maximise the percentage of informative patients.
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With 23000 new cases annually, the incidence of head and neck
squamous cell carcinoma (HNSCC) in France is one of the highest
in the world (Hill et al, 1997) because of smoking and alcohol
consumption (IARC, 1986, 1988). Early detection of HNSCC could
improve therapeutic results and reduce morbidity and mortality.
Loco-regional relapses occur in more than 30% of HNSCC patients
and mostly during the first 2 years after treatment (McCarty and
Million, 1994; Haas et al, 2001). Salvage treatments can only be
effective if recurrences are detected rapidly. The incidence of
second primary metachronous HNSCC attains 2–4% annually and
these lesions also need to be detected early (Panosetti et al, 1989;
Erkal et al, 2001). However, after surgery and/or radiotherapy,
clinical and radiological surveillance is difficult because of
anatomical modifications and fibrosis. Both clinical and nasofi-
broscopic examinations are only limited to the upper part of the
aero-digestive tract (Boysen et al, 1992). Cytological screening
(Ogden, 1997) has been developed by collecting saliva with or
without an oral mucosal brush. Recently, an encapsulated
oesopharyngeal brush (OPB) technique for cytological analysis
was developed to detect recurrent and metachronous oesophageal
carcinomas (Leoni-Parvex et al, 2000). Oesopharyngeal brush has
also been shown to be capable of collecting exfoliated cells from
oral or pharyngeal carcinoma. This technique, whose sensitivity
and specificity are high, appears to be safe and minimally invasive.
Head and neck squamous cell carcinoma is a multistep genetic
process (Califano et al, 1996; Mao et al, 1996a) during which proto-
oncogenes are activated and tumour-suppressor genes are
inactivated. Tri- and tetranucleotide microsatellite instability
(MI) is characterised by the insertion or deletion of one or more
repeat units of three or four nucleotides. These sporadic
microsatellite mutations are independent of mutations in mis-
match repair genes and reflect DNA damage caused by exposure to
carcinogens in tobacco smoke (Slebos et al, 2002). Microsatellite
instability is regarded as a clonal marker of HNSCC (Mao et al,
1994; Coulet et al, 2000), which can be used to detect small
amounts of tumour DNA (Forastiere et al, 2001). Microsatellite
instability is a qualitative variable that can be detected by PCR-
based techniques such as bandshift assays. The UT5085 marker
currently appears to be the most informative marker of MI in
HNSCC (Coulet et al, 2000). The p53 tumour-suppressor gene is
mutated in more than 50% of HNSCC (Temam et al, 2000).
Different PCR techniques have been described for the detection of
p53 mutations. The sensitivity and the reproducibility of PCR have
recently been reviewed (van Houten et al, 2000). The most
sensitive techniques, including cDNA cloning and specific
hybridisation, are very time consuming and are difficult to apply
in routine practice.
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yMolecular approaches have rarely been compared with conven-
tional cytological analysis in HNSCC (Mao et al, 1994). The aim of
the present study was to test the OPB for the detection of tumour
cells from the head and neck region, and to compare conventional
cytological evaluation with molecular analysis using two techni-
ques: analysis of MI at the UT5085 locus and direct sequencing of
p53.
MATERIALS AND METHODS
Patients and sample collection
Patients were referred to the Institut Gustave Roussy between July
1999 and June 2000. All patients underwent OPB sampling before
panendoscopy with oesophagoscopy, which excluded a second
oesophageal tumour. Oesopharyngeal brush sampling was per-
formed, as previously described (Leoni-Parvex et al, 2000). An
abrasive sponge wrapped in a capsule (Oesotest
s, Biodessa,
France) was first swallowed and then withdrawn with a string. It
was shaken in a saline fluid that was centrifuged over 10min at
3000g. The supernatant was discarded and the cell pellet was
retained. Part of this pellet was smeared onto three glass slides and
fixed in alcohol. Slides were stained using the Papanicolaou
method for cytological evaluation and the rest of the sediment was
frozen for biological studies. The institutional review board
approved the study, and informed consent was obtained from all
subjects.
In total, 56 fresh-frozen primary HNSCC biopsy samples were
collected during panendoscopy from 56 patients. All samples were
diagnosed as invasive HNSCC and samples containing more than
70% of tumour cells were selected in order to avoid microdissec-
tion. Normal mucosa biopsy specimens were also collected during
panendoscopy from five healthy patients, who were heavy smokers
and drinkers, but free of HNSCC. At the time of the initial
diagnosis, fresh blood was collected from patients in EDTA tubes
and lymphocytes were separated for use as normal DNA.
Cytological criteria
Cytological specimens were considered positive if there were low-
or high-grade squamous dysplastic cells or squamous carcinoma
cells, at least on one slide. This definition of positivity was based
on oeosophageal cytological criteria proposed by Shu (1983) and
used by others (Leoni-Parvex et al, 2000). The cytological
evaluation was considered negative only when there was no
significant cytonuclear atypia in squamous cells and if the majority
of cells were of the intermediate type.
Analysis of UT5085 microsatellite in tumour DNA and OPB
samples
DNA was extracted with the QIAamp Blood Kit (Qiagen,
Courtaboeuf, France). DNA quality was checked with GeneQuant
II (Amersham Pharmacia Biotech, Cambridge, UK). The UT5085
tetranucleotidic microsatellite was amplified with primers refer-
enced in the GenBank sequence database (accession number GDB
309286), as described (Coulet et al, 2000): (a) UT5085A, 50-
AAAGTGGGGATAAGGCAGC-30; and (b) UT5085B, 50-AGATGCA-
CAACACATACACG-30. The primer (a) UT5085A was labelled in
blue by 6-carboxy-fluorescein (FAM). Amplification was per-
formed in a 20-ml reaction volume with 0.5U HotStart Taq DNA
Polymerase (Qiagen, Courtaboeuf, France), 0.2mM deoxynucleo-
tide triphosphate, 3.2pmol of each forward and reverse primer,
2m M MgCl2, and 2mlo f1 0  Qiagen buffer. A total of 100ng of
DNA was used as a template for each sample. The mixtures were
denatured for 20min at 951C followed by 35 cycles at 951C for 30s,
541C for 30s and 721C for 30s. A final elongation was performed
for 10min at 721C. Amplified products were run in polyacrylamide
sequencing gels, ELLIOSEQ GEL (Laboratoires Ellios Bio Media,
Paris, France) mixed with 0.5ml of GENESCAN-500 ROX (Applied
Biosystems, Inc., Warrington, UK) and 2.5ml of formamide blue
after a 2min denaturing step at 941C. Polymerase chain reaction
(PCR) products were detected on the gel by laser fluorescence on
the ABI prism 377 DNA sequencer (Applied Biosystems, Inc.).
Data were analysed by Genescan analysis (Applied Biosystems,
Inc.).
All tumours and corresponding lymphocytes were amplified to
select unstable UT5085 samples. A normal mucosa biopsy speci-
men was used for the five control patients. Microsatellite instability
(MI) was defined as the presence of a new pattern in at least one
extra band in tumour DNA compared to lymphocyte DNA.
Patients with UT5085 MI in tumours were defined as informative
patients.
Oesopharyngeal brush material corresponding to all shifted
tumours was then amplified and coanalysed with tumour and
lymphocyte DNA to compare the different microsatellite patterns.
We also studied OPB samples from eight uninformative tumours
and from the five control subjects. Two observers assessed all
samples independently and borderline cases were repeated and
evaluated by densitometry.
p53 mutation detection in tumour DNA and OPB samples
Exons 2–11 were screened for mutations by denaturing high-
performance liquid chromatography (DHPLC) using the Wave
s
(Transgenomic, Inc., Omaha, USA). Tumours with a variant
chromatographic pattern were specifically amplified by PCR and
both strands were sequenced for each variant exon using the ABI
prism 377 DNA sequencer (Applied Biosystems, Inc.) with the Big
Dye Terminator sequencing kit (Applied Biosystems, Inc). Data
were analysed by Sequencing Analysis Software (Applied Biosys-
tems, Inc). All mutations were confirmed twice on both strands.
Oesopharyngeal brush material from patients harbouring a p53-
mutated tumour was analysed to search for the same p53 mutation.
We used direct sequencing of the putative mutated exon under the
same conditions as in the tumour.
Statistical analysis
w
2 tests were used to compare qualitative variables.
RESULTS
Population
In total, 56 patients with a unique HNSCC were prospectively
entered into the study. Primary tumour sites were: the oral cavity,
oropharynx, larynx and hypopharynx in 13, 23, 12 and eight cases,
respectively. There were 18 T1-2 and 38 T3-4 lesions (Table 1). Five
healthy control patients, who were heavy smokers and drinkers but
free of HNSCC, were also studied.
Molecular markers in primary tumours
UT5085 tetranucleotide MI was analysed in all tumours and
corresponding lymphocytes (Table 1). Tumours were informative
(i.e. exhibited a bandshift) in only 14 out of 56 (25%) patients and
not in five controls. p53 mutations were detected in 31 out of 56
(55%) tumours. Of the p53 mutations, 21 (68%) were missense
mutations, nine (29%) were nonsense mutations and one (3%) was
a silent mutation. Details of p53 mutations are shown in Table 2.
There was no relation between molecular analysis results and the T
stage or tumour location. No significant correlation was found
between p53 mutations and UT5085 MI: nine out of 14 (64%)
tumours with UT 5085 MI were p53 mutated vs 22 out of 42
without MI (52%; P¼0.6).
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All cytological samples were available for interpretation. Of the 56
OPB DNA samples, 20 (36%) were positive at cytological
examination: 13 with squamous carcinoma cells and seven with
dysplastic cells (Table 1). There was no relation between the results
of the cytological analysis and the T stage or tumour location.
Oesopharyngeal brush cytology was normal in all five control
subjects.
Oesopharyngeal brush DNA was available for the evaluation of
UT5085 tetranucleotide MI in 13 out of 14 informative patients. In
these informative patients, a bandshift, similar to that observed in
the primary tumour, was detected in 11 out of 13 (85%) OPB DNA
Table 1 Clinical and biological characteristics of the 56 HNSCCs, according to cytological and biological study of pharyngo-oesophageal brushing
(Oesotest
s)
Cytology Microsatellite UT5085 p53 mutations
Pts no. Tumour site T stage Oesotest Tumour Oesotest Tumour Oesotest
1 Oropharynx T4 Carcinoma Shift Shift Mut Neg
2 Oropharynx T3 Neg Shift Shift Mut Mut
3 Oropharynx T4 Neg Shift Shift Mut Neg
4 Larynx T2 Carcinoma Shift Shift Mut Neg
5 Larynx T4 Carcinoma Shift Shift Mut Neg
6 Hypopharynx T2 Neg Shift Shift Mut Neg
7 Oral cavity T4 High-grade dysplasia Shift Shift Mut Neg
8 Oropharynx T4 Carcinoma Shift Shift Wild ND
9 Oropharynx T2 Carcinoma Shift Shift Wild ND
10 Hypopharynx T4 Neg Shift Shift Wild ND
11 Oral cavity T4 Neg Shift Shift Wild ND
12 Larynx T3 Neg Shift Neg Mut Neg
13 Oropharynx T4 Neg Shift Neg Wild ND
14 Oropharynx T3 Neg Shift No DNA Mut No DNA
15 Hypopharynx T4 Carcinoma Neg Neg Mut Mut
16 Oropharynx T3 Carcinoma Neg Neg Mut Neg
17 Oropharynx T4 Neg Neg ND Mut Neg
18 Oropharynx T3 Neg Neg ND Mut Neg
19 Oropharynx T4 High-grade dysplasia Neg ND Mut Neg
20 Oropharynx T4 Carcinoma Neg ND Mut Neg
21 Oropharynx T2 Neg Neg ND Mut Neg
22 Oropharynx T2 Neg Neg ND Mut Neg
23 Oropharynx T3 Low-grade dysplasia Neg ND Mut Neg
24 Oropharynx T2 Carcinoma Neg ND Mut Neg
25 Larynx T3 Carcinoma Neg Neg Mut Neg
26 Larynx T3 Neg Neg Neg Mut Neg
27 Larynx T4 Neg Neg ND Mut Neg
28 Larynx T2 Low-grade dysplasia Neg ND Mut Neg
29 Hypopharynx T2 Carcinoma Neg ND Mut Neg
30 Hypopharynx T4 Neg Neg Neg Mut Neg
31 Hypopharynx T1 Neg Neg Neg Mut ND
32 Hypopharynx T4 Neg Neg ND Mut Neg
33 Oral cavity T4 Neg Neg ND Mut Neg
34 Oral cavity T4 Neg Neg Neg Mut Neg
35 Oral cavity T3 Neg Neg Neg Mut Neg
36 Oral Cavity T3 Neg Neg ND Mut Neg
37 Oropharynx T1 Carcinoma Neg Neg Wild ND
38 Oropharynx T3 Neg Neg ND Wild ND
39 Oropharynx T2 Neg Neg ND Wild ND
40 Oropharynx T2 Neg Neg ND Wild ND
41 Oropharynx T3 Neg Neg ND Wild ND
42 Oropharynx T2 Neg Neg ND Wild ND
43 Oropharynx T1 Neg Neg ND Wild ND
44 Larynx T4 Neg Neg ND Wild ND
45 Larynx T2 Low-grade dysplasia Neg ND Wild ND
46 Larynx T3 High-grade dysplasia Neg ND Wild ND
47 Larynx T4 Neg Neg ND Wild ND
48 Larynx T1 Neg Neg Neg Wild ND
49 Hypopharynx T4 Neg Neg ND Wild ND
50 Oral cavity T2 Neg Neg ND Wild ND
51 Oral cavity T4 Neg Neg ND Wild ND
52 Oral cavity T4 Neg Neg ND Wild ND
53 Oral cavity T4 High-grade dysplasia Neg ND Wild ND
54 Oral cavity T4 Carcinoma Neg ND Wild ND
55 Oral cavity T3 Neg Neg ND Wild ND
56 Oral cavity T2 Neg Neg ND Wild ND
Neg¼negative; ND¼not done; shift¼microsatellite instability at UT5085; Mut¼p53 mutation; Wild¼p53 wild type.
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detected at cytological analysis in only six out of 13 (46%) patients.
In informative patients all positive OPB DNA samples at
cytological evaluation were also positive at molecular analysis of
UT5085 (Table 3), and the two samples found to be negative at
molecular analysis were also negative at cytological analysis
(Figure 1B). In this subgroup, the molecular analysis with the
UT5085 marker was more sensitive than the cytological analysis
(P¼0.03). Molecular analysis with UT5085 was negative for the 13
controls: five healthy subjects and eight uninformative patients.
In the subgroup of 31 patients exhibiting a p53 mutation, DNA
was available for 29 OPB samples. Direct sequencing of p53 was
able to detect tumour DNA in OPB samples from only two out of
29 (7%) samples, whereas cytological evaluation was positive in 13
out of 29 OPB samples (45%; Table 4). Of these 13 OPB DNA
samples, 12 were positive at cytological analysis and negative at
direct sequencing of p53.
DISCUSSION
Oesopharyngeal brush with cytological analysis was mainly
developed in China for mass screening of oesophageal carcinoma
(Dowlatshahi et al, 1978; Jaskiewicz et al, 1987). The sensitivity of
this technique ranges from 40 to 70% and its specificity from 90 to
99%. Several teams have used the OPB to detect second primary
tumours during the follow-up of patients treated for HNSCC,
because clinical examination is difficult and is limited to the upper
part of the aero-digestive tract. The OPB has indeed proved very
sensitive for the detection of new primary lesions. In the study by
Pellanda et al (1999), none of the 254 patients with negative OPB
cytology developed an oesophageal tumour. Among the 25
asymptomatic patients with positive OPB cytology, a premalignant
or early oesophageal tumour was detected in 20 cases. Interest-
ingly, in the same study 10 clinically unsuspected oral or
pharyngeal carcinoma were also detected. These data suggest that
exfoliated cells from the upper part of the aero-digestive tract can
be swallowed and sampled with the OPB. This technique for
collecting tumour cells could therefore be as efficient as saliva
sampling with the added advantage of allowing access to the
hypopharynx and oesophagus. In the present study, the OPB was
used before endoscopy and the initial biopsy. The oesophagoscopy
excluded a second primary tumour of the oesophagus.
Table 2 p53 mutations in 31 patients with HNSCC
Patients no. Exon Codon
a Sequence Amino acid
28 4 35 Deletion 1bp Frameshift
35 4 111 CTG-CAG L-Q
18 5 125 ACG-AGG T-R
27 5 126 TAC-TGC Y-C
31 5 134 TTT-GTT F-V
30 5 146 TGG-TAG W-Stop
36 5 179 CAT-CTT H-L
34 5 183 TCA-TGA S-Stop
3 5 187 GGT-GTT G-V
1 6 193 CAT-CTT H-L
12 6 204 GAG-TAG E-Stop
7 7 245 GGC-GAC G-V
2 7 247 AAC-AAT N-N
24 7 248 CGC-CTG R-L
19 7 248 CGG-CAG R-L
15 7 257 Insertion 1bp Frameshift
26 8 270 TTT-TCT F-S
32, 33, 20 8 273 CGT-TGT R-C
14 8 273 CGT-CAT R-H
23 8 275 TGT-TTT C-F
4, 29, 17, 21 8 282 CGG-TGG R-W
5 9 319 AAG-TAG K-Stop
16 9 321 Deletion 1bp Frameshift
25 9 331 CAG-TAG Q-Stop
6 9 327 or 328 Insertion 1bp Frameshift
22 10 Intron 11 17708 A-T Silent
aFirst codon of the frameshift mutation.
bp¼base pair.
Table 3 Comparison of cytological examination with Papanicolaou
staining and microsatellite analysis of pharyngo-oesophageal brush samples
for the 13 patients whose tumour exhibited an MI at UT5085
Cytology
Positive
a Negative Total
Microsatellite UT5085
Shift 6 5 11
No shift 0 2 2
Total 6 7 13
Molecular analysis was more sensitive than cytological study (P¼0.03).
aPositive¼low- or high-grade squamous dysplasia cells or squamous cells carcinoma.
Table 4 Comparison of cytological examination with Papanicolaou
staining and p53 direct sequencing of pharyngo-oesophageal brushing for
the 29 patients with p53 mutated tumours
Cytology
Positive
a Negative Total
Mutated p53
Yes 1 1 2
No 12 15 27
Total 13 16 29
aPositive¼low- or high-grade squamous dysplasia cells or squamous cells carcinoma.
Figure 1 Microsatellite UT5085 of paired tumour, lymphocyte and
pharyngo-oesophageal brushing (Oesotest
s). (A) Patient number 5 who
had an informative tumour (bandshift) and a positive brushing with the
same pattern (same bandshift as tumour). (B) Patient number 12 who had
an informative tumour and a negative brushing.
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the OPB in detecting tumour cells from inaccessible parts of the
head and neck region and (ii) to compare cytological vs molecular
analysis for the detection of tumour exfoliated cells in a population
of 56 HNSCC patients.
We confirm that tumour cells exfoliated from the head and neck
region can be sampled in the oesophagus. It is noteworthy that
OPB detected tumour cells and/or tumour DNA in seven out of 12
laryngeal carcinoma in the oesophagus, as shown in Table 1.
Perhaps, this easy and low-invasive technique could be tested in
bronchial carcinoma.
The results of the molecular analysis of OPB samples are directly
linked to the technique used. In this study, we tested two different
techniques: MI analysis and p53 direct sequencing. Microsatellite
alterations on selected tetranucleotide markers are common in
non-small-cell lung, head and neck, and bladder carcinoma (Mao
et al, 1994). The generation of a novel allele through the insertion
or deletion of a short tandem repeat creates a new band that is only
present in neoplastic cells. This new band is easier to detect than a
subtle change as in loss of heterozygosity. Our results show that for
informative patients, molecular analysis with UT 5085 appears to
be more sensitive than cytology for the detection of exfoliated
tumour cells: abnormal DNA was detected in 11 out of 13 OPB
samples, compared to six out of 13 abnormal or tumour cells
detected at cytology (P¼0.03). These results will prompt us to use
panels of microsatellite markers, in order to increase the sensitivity
of the genetic analysis. Using a panel of 23 informative
microsatellite markers, Spafford et al (2001) found a much higher
rate (57 vs 25%) of MI in HNSCC patients.
Mao et al (1994), using a panel of nine tri- and tetranucleotide
markers, demonstrated the interest of MI as clonal markers for the
detection of HNSCC cells. They detected identical microsatellite
alterations in corresponding serum, sputum and surgical margins.
In patients treated for bladder carcinoma, microsatellite analysis of
urine sediment was found to be more efficient than cytological
analysis: primary bladder cancer was identified in 19 out of 20
patients at microsatellite analysis, whereas only nine out of 18
lesions were detected at cytological analysis (Mao et al, 1996b).
Thus, in these informative patients,the difference between the two
techniques (conventional cytological analysis and microsatellite
analysis) is similar to that found in the present study. Studying
pretreatment oral rinses and swab samples from HNSCC patients,
Spafford et al detected MI in 24 out of 25 (96%) informative
patients. Like most authors, they did not, however, compare
microsatellite detection and cytology (Spafford et al, 2001). Our
study shows that microsatellite-based molecular analysis can be
positive in cytologically negative samples.
In our experience, the bandshift profile detected in OPB samples
must be compared with that of the primary tumour. DNA
extracted from exfoliated cells can undergo degradation and it is
mandatory that bandshifts be distinguished from artefacts.
Microsatellite-based molecular analysis should be efficient for
early detection of recurrences of a tumour that has already been
analysed. However, unlike cytology, this technique will be difficult
to use for the detection of second primary tumours, which do not
necessarily share the same genetic alterations.
Conversely and based on the concept of field cancerisation, we
cannot exclude the possibility that cells other than those of the
primary tumour share the same genetic alterations. Mucosa
exhibiting a normal appearance in patients with early cancer or
premalignant lesions has been shown to harbour occult micro-
satellite alterations (Califano et al, 1996). However, we have
evidenced that the molecular analysis of UT5085 in OPB samples
from eight patients with an uninformative tumour and from five
heavy smokers free of HNSCC were all negative.
Although we found a 55% rate of p53 mutations in primary
tumours, which is similar to that usually observed in HNSCC, only
a 7% rate of p53 mutations was found in OPB samples from
patients with p53 mutations. As shown by Boyle et al (1994), p53-
mutated cells are present in the saliva of HNSCC patients. They
used another technique, namely cloning of p53 sequences followed
by hybridisation with specific radio-labelled oligonucleotide
probes (van Houten et al, 2000). Two independent papers have
demonstrated the clinical relevance of that technique by investi-
gating surgical margins of tumours from head and neck cancer
patients (Brennan et al, 1995; Partridge et al, 2000). However, this
sensitive and clinically validated technique is very time consuming
and cannot be used in routine practice. Our results also confirm
that direct sequencing of p53 is not a sensitive technique for
detecting small amounts of tumour DNA. In the present work, we
found no association between UT 5085 MI and p53 mutations in
the primary tumour. This is in contrast with the results reported
by Ahrendt et al (2000) in non-small-cell lung cancer.
The MI rate for one marker is low. As this study clearly indicates
that microsatellite-based techniques could be efficient for detecting
early recurrences, we could increase the number of MI markers, as
already performed by Spafford et al (2001), in order to maximise
the rate of informative patients.
Other molecular markers have been tested for the diagnosis of
minimal residual disease in HNSCC. A panel of molecular markers
based on promoter hypermethylation of selected genes (Sanchez-
Cespedes et al, 2000; Rosas et al, 2001) could be of particular
interest as well as mutations in mitochondrial DNA (Fliss et al,
2000; Sanchez-Cespedes et al, 2001; Ha et al, 2002). This study on
patients with known HNSCC is the first step towards a molecular
diagnosis test for the follow-up of patients with HNSCC. In the
near future, these cytodiagnosis techniques associated with
molecular analysis could be tested in populations of heavy
drinkers and smokers. Patients with asymptomatic tumours
detected with these molecular markers could thus benefit from
early treatment.
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